

Date: 13 November 2020

To

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400051

Symbol: Banka

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 13.11.2020

Ref.: Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

With reference to the above subject and pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that in the meeting of the Board of Directors of the Company held today i.e. Friday, 13 November 2020, the board of directors of the company inter-alia discussed, considered and approved the following:

- Standalone Un-audited Financial Results for the quarter and half year ended 30 September 2020
- Limited Review Report submitted by the Statutory Auditors of the Company for the quarter and half year ended 30 September 2020
- Statement of assets and liabilities and Cash Flow Statement for the quarter and half year ended 30 September 2020.

The meeting commenced at 12 PM and concluded at 2.15PM.

Kindly take the same on record.

Thanking you

Yours truly
Thank you!

For Banka BioLoo Limited



T V Rama Krishna
CFO and Whole-Time Director
DIN: 07977695



Encls as above

Date: 13 November 2020

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400051

Symbol: Banka

Dear Sir/Madam,

Sub: Submission of Un-Audited Financial Results for the quarter and half-year ended 30 September 2020 together with Statement of Assets and Liabilities and Cash Flow Statement as on 30 September 2020.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Circular(s) we herewith enclose the following:

- Standalone Un-audited Un-audited Financial Results for the quarter and half year ended 30 September 2020
- Limited Review Report submitted by the Statutory Auditors of the Company for the quarter and half year ended 30 September 2020
- Statement of assets and liabilities and Cash Flow Statement for the quarter and half year ended 30 September 2020.

Kindly take the same on record.

Yours truly,

For Banka BioLoo Limited

T V Rama Krishna
CFO and Whole-Time Director
DIN: 07977695

*Encls as above*



Independent Auditor's Review Report on Half Yearly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of **Banka BioLoo Limited**,

We have reviewed the accompanying Statement of Unaudited Financial Results of **BANKA BIOLOO LIMITED** for the half year ended 30 September 2020 and the Unaudited Statement of Assets and Liabilities as at 30 September 2020 ("the statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India, other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular'), including the manner in which it is to be disclosed, or that it contains any material misstatements.

For PRSV & Co LLP
Chartered Accountants
Firm Registration No. S200016


Y. Venkateswarlu
Partner
M. No. 222068



Place: Hyderabad
Date: 13 November 2020

UDIN: 20222068 AAAADS8428

BANKA BIOLOO LIMITED

Statement of Assets and Liabilities as at 30 September 2020

(Rs. In Lakhs)

S.No	Particulars	Un Audited	Audited
		As at 30 September, 2020	As at 31 March, 2020
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
(a)	Share capital	1,028	411
(b)	Reserves and surplus	1,856	2,378
		2,884	2,790
2	Non-current liabilities		
(a)	Long-term borrowings	780	753
(b)	Deferred tax liabilities (Net)	-	5
(c)	Long-term provisions	50	50
		829	807
3	Current liabilities		
(a)	Short-term borrowings	70	179
(b)	Trade payables	127	320
(c)	Other current liabilities	519	582
(d)	Short-term provisions	-	-
		716	1,081
	TOTAL EQUITY AND LIABILITIES	4,430	4,677
B	ASSETS		
1	Non-current assets		
(a)	Property, Plant and Equipment		
(i)	Tangible Assets	376	400
(ii)	Intangible Assets	14	2
(iii)	Capital work in Progress	-	-
(b)	Investments	1	
(c)	Deferred tax liabilities (Net)	3	
(d)	Long-term loans and advances	502	821
		895	1,223
2	Current assets		
(a)	Inventories	438	376
(b)	Trade receivables	1,489	1,497
(c)	Cash and cash equivalents	291	433
(d)	Short-term loans and advances	885	436
(e)	Other current assets	432	712
		3,534	3,454
	TOTAL ASSETS	4,430	4,677

For PRSV & Co. LLP
Chartered Accountants
FRN No. S-200016

Y. Venkateswarlu
Partner
M.No.222068

Place: Hyderabad
Date: 13.11.2020




FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka *T.V. Rama Krishna*

Vishal Murarka
WTD & CEO
DIN:06729485

T.V. Rama Krishna
WTD & CFO
DIN: 07977695



BANKA BIOLOO LIMITED

Statement of Un Audited Results for the Half Year ended 30 September 2020

(Rs. In Lakhs)

S. No	Particulars	Half year ended			Year ended
		30.09.2020 Unaudited	31.03.2020 Audited	30.09.2019 Unaudited	31.03.2020 Audited
1	Income				
	Gross Revenue from operations	1,600	3,194	2,310	5,504
	Less:Duties & Taxes	(276)	(430)	(287)	(718)
	Net Revenue from Operations	1,324	2,764	2,023	4,787
	Other operating revenue	-	-	-	-
	Other income	13	28	17	45
	Total Income	1,337	2,792	2,040	4,832
2	Expenses				
	Cost of materials consumed	216	517	419	937
	Changes in inventories of finished goods & work-in-progress	(47)	(43)	(15)	(57)
	Employee benefits expense	619	1,217	996	2,214
	Depreciation and amortisation expense	26	25	21	47
	Finance costs	66	58	37	95
	Other expenses	315	546	289	835
	Total expenses	1,196	2,322	1,748	4,069
3	Profit/(loss) before tax	141	470	293	763
4	Tax expense				
	(1) Current tax	34	89	71	160
	(2) MAT Credit	-	0	2	2
	(3) Deferred tax	-8	(4)	-0	-4
	Total Tax expense	26	85	73	158
5	Profit after tax	115	385	220	605
6	Paid up equity share capital (Face value Rs. 10/- each)	1,028.11	411.24	411.24	411.24
7	Earnings per share				
	Basic and Diluted Earnings per share (in Rs.)	1.12 (Not annualised)	3.74 (Not annualised)	2.14 (Not annualised)	5.88 (Annualised)

See accompanying notes to the financial results


 For PRSV & Co. LLP
Chartered Accountants
FRN No. S-200016

 Y. Venkateswarlu
Partner
M.No.222068

 Place: Hyderabad
Date: 13.11.2020


FOR & ON BEHALF OF BOARD OF DIRECTORS

 Vishal Murarka
WTD & CEO
DIN:06729485

 T.V. Rama Krishna
WTD & CFO
DIN: 07977695


BANKA BIOLOO LIMITED

Un Audited Cash flow statement for the Half Year ended 30 September 2020

(Rs. In Lakhs)

Particulars	Half Year ended 30.09.2020	Year ended 31.03.2020
A. Cash flows from/(used in) operating activities		
Net profit before tax	141	763
Adjustments for:		
Depreciation	26	47
Finance cost	66	95
Impairment of assets	-	3
Interest received	(10)	(43)
Operating profit before working capital changes	223	864
<i>Changes in operating assets and liabilities</i>		
(Increase) in trade receivables	8	(525)
(Increase)/decrease in inventories	(61)	(134)
(Increase)/decrease in long term loans and advances	319	(327)
(Increase)/decrease in short term loans and advances	(449)	(234)
(Increase)/decrease in other current assets	280	(616)
(Increase)/decrease in Investments	(1)	
Increase/(Decrease) in trade payables	(193)	200
Increase/(Decrease) in other current liabilities	-62	212
(Decrease) in short term provisions	(34)	(212)
(Decrease)/increase in long term provisions	-	32
Cash (used in)/from operating activities	30	(740)
Tax paid	-	(141)
Net cash (used in)/ from operating activities	30	(600)
B. Cash flow from/(used in) investing activity		
Purchase of fixed assets	(13)	(141)
Interest received	10	43
Net cash (used in)/from investing activities	(3)	(98)
C. Cash flows from/(used in) financing activities		
Repayment / proceeds of long term borrowings	6	675
Increase/(decrease) in short term borrowing	(109)	179
Interest paid	(66)	(95)
Net cash (used in)/from financing activities	(169)	759
Net increase/(decrease) in cash and cash equivalents	(142)	62
Add: Cash and cash equivalents at the beginning of the year	433	372
Less: Bank deposits with less than 12 months maturity	127	409
Cash and cash equivalents at the end of the year	164	25

As per our report of even date attached

 For PRSV & Co.LLP
 Chartered Accountants
 FRN No: S-200016


 Y. Venkateswarlu
 Partner
 M.No. 222068


For and on behalf of Board of Directors


 Vishal Murarka
 WTD & CEO
 DIN: 05017358


 T.V. Rama Krishna
 WTD and CFO
 DIN: 07977695

 Place : Hyderabad
 Date: 13.11.2020

Notes to the Financial Results for the Half-Year ended 30th September 2020:

1. The above Financial Results and statement of Assets and Liabilities were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13th November 2020.
2. The above Financial Results and the Statement of Assets & Liabilities have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
3. The financial results for the half year ended 30th September 2020 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31st March 2020.
4. The company does not have separate reportable segments as per the Accounting Standards 17 on "Segment Reporting" notified under companies (Accounting standard) Rules, 2014.
5. During the financial year ended 31st March 2018, the company has completed its initial public Offer (IPO) of 10,98,000 Equity Shares of Rs.10/- each at a price of Rs.115 per share (including a premium of Rs.105 per share).
6. Proceeds from Initial Public Offer of Equity Shares have been utilized as under:

S. No	Particulars	Projected Utilization of Funds as per Prospectus	Actual Utilization of Funds till 30.09.2020	Deviation/ Variation (if any)
1	Long Term Working Capital Requirement	797.88	797.88	
2	General Corporate Purpose	231.62	231.62	
3	Issue Related Expenses-Company portion	61.10	61.08	
4	Capital expenditure at existing inoculum at Aler	75.21	75.21	
5	Capital expenditure at proposed new unit at Ibrahimpatnam	96.89	26.14	
	Total	1,262.70	1191.92	-

7. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For PRSV & Co. LLP
Chartered Accountants
FRN No. S-200016



Y. Venkateswarlu
Partner
M. No .222068



For Banka BioLoo Limited


Vishal Murarka
WTD & CEO
DIN: 05017358


T.V Ramakrishna
WTD & CFO
DIN: 07977695



Place: Hyderabad
Date: 13th November 2020